About NF-kappa-B inhibitor epsilon
NF-kappa-B inhibitor epsilon (NFKBIE) is a protein
from Homo sapiens identified by UniProt accession
O00221, 500 residues long.
MolForge cross-references it against 0 known binders and
204 disease associations.
Target properties
| Protein name | NF-kappa-B inhibitor epsilon |
| UniProt accession | O00221 |
| Gene | NFKBIE |
| Organism | Homo sapiens |
| Length | 500 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (204)
Diseases linked to this target (Open Targets).
- chronic lymphocytic leukemia · score 0.50
- diffuse large B-cell lymphoma · score 0.44
- melanoma · score 0.40
- nodular melanoma · score 0.37
- skin basal cell carcinoma · score 0.37
- cutaneous melanoma · score 0.37
- desmoplastic melanoma · score 0.37
- lymphoma · score 0.35
- rheumatoid arthritis · score 0.35
- lymphoid leukemia · score 0.31
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O00221-F1 | alphafold | PREDICTED | 61.64 | — |
Amino-acid sequence (500 residues)
MNQRRSESRP GNHRLQAYAE PGKGDSGGAG PLSGSARRGR GGGGAIRVRR PCWSGGAGRG GGPAWAVRLP TVTAGWTWPA LRTLSSLRAG PSEPHSPGRR PPRAGRPLCQ ADPQPGKAAR RSLEPDPAQT GPRPARAAGM SEARKGPDEA EESQYDSGIE SLRSLRSLPE STSAPASGPS DGSPQPCTHP PGPVKEPQEK EDADGERADS TYGSSSLTYT LSLLGGPEAE DPAPRLPLPH VGALSPQQLE ALTYISEDGD TLVHLAVIHE APAVLLCCLA LLPQEVLDIQ NNLYQTALHL AVHLDQPGAV RALVLKGASR ALQDRHGDTA LHVACQRQHL ACARCLLEGR PEPGRGTSHS LDLQLQNWQG LACLHIATLQ KNQPLMELLL RNGADIDVQE GTSGKTALHL AVETQERGLV QFLLQAGAQV DARMLNGCTP LHLAAGRGLM GISSTLCKAG ADSLLRNVED ETPQDLTEES LVLLPFDDLK ISGKLLLCTD
Explore NF-kappa-B inhibitor epsilon with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets